British investment firm secures $250M to help fund development of new dementia therapeutics
British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class therapeutics for dementia, the second such fund the venture capitalists have put together.
British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class therapeutics for dementia, the second such fund the venture capitalists have put together.
